Common adverse events were anemia (74.6%), edema (67.8%), neutropenia (52.2%), liver function disorder (53.3%), nausea (18.9%), diarrhea (15.5%), fatigue (10%). Conclusion: Imatinib induced a sustained objective response in over half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.